CannabisNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Reports Encouraging Bioavailability Results from TurboCBD™ Study
Drug delivery platform innovator Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP) this morning reported noteworthy bioavailability results from its randomized, placebo-controlled, double-blind European human clinical study that evaluated TurboCBD™. TurboCBD™ is a proprietary, DehydraTECH™ powered, cannabidiol ("CBD") fortified hemp oil capsule developed by Lexaria. The study evaluated the degree and speed of CBD absorption into blood plasma and potential cardiovascular and cognitive performance enhancement in 12 healthy male volunteers. The study compared the 90 mg dose of Lexaria's TurboCBD™ to a 90 mg dose of a positive control formulation without Lexaria's DehydraTECH™ technology. Per the report, Lexaria's TurboCBD™ capsules continued to…